Gyre Therapeutics, Inc. Net Income (Loss) Attributable to Noncontrolling Interest
Gyre Therapeutics, Inc. (GYRE) reported Net Income (Loss) Attributable to Noncontrolling Interest of -$3.67 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToNoncontrollingInterest · last filed 2026-08-07
- Gyre Therapeutics, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$3.67M.
- Gyre Therapeutics, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$1.17M, a 212.64% decline year-over-year.
- Gyre Therapeutics, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2025-12-31 was $357.00K, a 46.56% decline year-over-year.
- Gyre Therapeutics, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2025-09-30 was $2.33M, a 34.30% increase year-over-year.
- Gyre Therapeutics, Inc. net income (loss) attributable to noncontrolling interest for fiscal 2025 was $4.85M, a 16.51% decline from fiscal 2024.
- Gyre Therapeutics, Inc. net income (loss) attributable to noncontrolling interest for fiscal 2024 was $5.81M, a 22.00% decline from fiscal 2023.
- Gyre Therapeutics, Inc. net income (loss) attributable to noncontrolling interest for fiscal 2023 was $7.45M, a 270.43% increase from fiscal 2022.
- Gyre Therapeutics, Inc. net income (loss) attributable to noncontrolling interest for fiscal 2022 was $2.01M.
| Period end | Net Income (Loss) Attributable to Noncontrolling Interest 3 month | Net Income (Loss) Attributable to Noncontrolling Interest 3 month as first filed | Net Income (Loss) Attributable to Noncontrolling Interest 6 month | Net Income (Loss) Attributable to Noncontrolling Interest 6 month as first filed | Net Income (Loss) Attributable to Noncontrolling Interest 9 month | Net Income (Loss) Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$3.67M 10-Q · filed 2026-08-07 | -$11.95M 10-Q · filed 2026-08-07 | -$4.47M derived: sum of 3 quarters · filed 2026-08-07 | -$2.15M derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2026-03-31 | -$1.17M 10-Q · filed 2026-05-08 | -$810.00K derived: sum of 2 quarters · filed 2026-05-08 | $1.52M derived: sum of 3 quarters · filed 2026-05-08 | -$1.32M derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2025-12-31 | $357.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $2.68M derived: sum of 2 quarters · filed 2026-03-13 | -$152.00K derived: sum of 3 quarters · filed 2026-08-07 | $4.85M 10-K · filed 2026-03-13 | ||
| 2025-09-30 | $2.33M 10-Q · filed 2025-11-07 | -$509.00K derived: sum of 2 quarters · filed 2026-08-07 | $4.50M 10-Q · filed 2025-11-07 | $1.20M derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2025-06-30 | -$2.83M 10-Q · filed 2026-08-07 | $1.13M 10-Q · filed 2025-08-11 | -$2.64M 10-Q · filed 2026-08-07 | $2.17M 10-Q · filed 2025-08-11 | -$1.13M derived: sum of 3 quarters · filed 2026-08-07 | $601.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $1.04M 10-Q · filed 2026-05-08 | $1.70M derived: sum of 2 quarters · filed 2026-05-08 | $3.44M derived: sum of 3 quarters · filed 2026-05-08 | $4.45M derived: sum of 4 quarters · filed 2026-05-08 | ||
| 2024-12-31 | $668.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $2.40M derived: sum of 2 quarters · filed 2026-03-13 | $3.41M derived: sum of 3 quarters · filed 2026-03-13 | $5.81M 10-K · filed 2026-03-13 | ||
| 2024-09-30 | $1.73M 10-Q · filed 2025-11-07 | $2.74M derived: sum of 2 quarters · filed 2025-11-07 | $5.14M 10-Q · filed 2025-11-07 | $5.17M derived: sum of 4 quarters · filed 2025-11-07 | ||
| 2024-06-30 | $1.01M 10-Q · filed 2025-08-11 | $3.41M 10-Q · filed 2025-08-11 | $3.44M derived: sum of 3 quarters · filed 2025-08-11 | $6.98M derived: sum of 4 quarters · filed 2025-08-11 | ||
| 2024-03-31 | $2.40M 10-Q · filed 2025-05-09 | $2.43M derived: sum of 2 quarters · filed 2025-05-09 | $5.97M derived: sum of 3 quarters · filed 2025-05-09 | $7.88M derived: sum of 4 quarters · filed 2025-05-09 | ||
| 2023-12-31 | $29.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $3.56M derived: sum of 2 quarters · filed 2025-03-17 | $5.48M derived: sum of 3 quarters · filed 2025-03-17 | $7.45M 10-K · filed 2025-03-17 | ||
| 2023-09-30 | $3.53M 10-Q · filed 2024-11-13 | $5.45M derived: sum of 2 quarters · filed 2024-11-13 | $7.42M 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | $1.92M 10-Q · filed 2024-08-13 | $3.89M 10-Q · filed 2024-08-13 | ||||
| 2023-03-31 | $1.97M 10-Q · filed 2024-05-13 | |||||
| 2022-12-31 | $2.01M 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |